Related Experiment Videos
The clinical experience with antiangiogenic agents
1Lombardi Cancer Center, Georgetown University Hospital, Washington DC 20007, USA.
Abstract:
Antiangiogenic agents have been recently recognized to be potentially useful in the treatment of malignant processes. There has been a resulting flood of these agents into the clinical research field, forcing researchers to consider the unique problems which these agents pose. As these are agents with a novel, angiostatic mechanism of action, new clinical trial designs may become necessary to move these agents from the phase 1 level on to clinical use. Currently, several of these agents are being or have been tested in clinical trials. In this article, we review the available clinical data with antiangiogenic agents from other investigators, and our own experience with pentosan polysulfate.
Insights
Antiangiogenic agents show promise for cancer treatment, but novel clinical trial designs are needed. This review examines current data and experience with pentosan polysulfate.
Area of Science:
- Oncology
- Pharmacology
Background:
- Antiangiogenic agents are recognized for potential use in treating malignant processes.
- A significant number of these agents are entering clinical research.
- Their novel angiostatic mechanism presents unique challenges for clinical application.
Purpose of the Study:
- To review existing clinical data on antiangiogenic agents.
- To discuss the challenges and potential necessity for new clinical trial designs.
- To present personal experience with pentosan polysulfate.
Main Methods:
- Review of published clinical trial data on antiangiogenic agents.
- Analysis of clinical research challenges posed by these agents.
- Inclusion of investigator's own experience with pentosan polysulfate.
Main Results:
- Several antiangiogenic agents are currently in or have completed clinical trials.
- The review synthesizes available clinical data from various sources.
- Personal experience with pentosan polysulfate is incorporated.
Conclusions:
- Antiangiogenic agents require careful consideration regarding clinical trial design.
- Further research and data are necessary to optimize their use in cancer therapy.
- Pentosan polysulfate represents one agent within this evolving therapeutic class.